Physician profile
Gary Manko
NPI 1588612139
$4,637.53
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,883 · 2020: $752 · 2021: $1,217 · 2022: $704 · 2024: $81.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $81.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $81.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $651.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $429.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $376.75 | 2019-2022 | |
| Lilly USA, LLC | $374.56 | 2019-2022 | |
| Amarin Pharma, INC. | $325.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $287.10 | 2019-2021 | |
| Amgen INC. | $276.47 | 2019-2021 | |
| Abbvie INC. | $270.75 | 2021-2022 | |
| Pfizer INC. | $257.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $228.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $195.20 | 2019-2021 | |
| Astellas Pharma US INC | $190.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.78 | 2019-2021 | |
| Gilead Sciences, INC. | $81.32 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $80.12 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $70.54 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.39 | 2019-2021 | |
| Allergan, INC. | $37.83 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $34.67 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.45 | 2019 | |
| Daiichi Sankyo INC. | $28.25 | 2019-2020 | |
| Abbott Laboratories | $26.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $26.08 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.27 | 2019 | |
| Sanofi Pasteur INC. | $17.84 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.36 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Manko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.